- Home
- RMBI vs SAVA Comparison
RMBI vs SAVA Comparison
Compare RMBI & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- SAVA
- Stock Information
- Founded
- RMBI 1887
- SAVA 1998
- Country
- RMBI United States
- SAVA United States
- Employees
- RMBI N/A
- SAVA N/A
- Industry
- RMBI Major Banks
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- RMBI Finance
- SAVA Health Care
- Exchange
- RMBI Nasdaq
- SAVA Nasdaq
- Market Cap
- RMBI 149.2M
- SAVA 134.2M
- IPO Year
- RMBI 2019
- SAVA N/A
- Fundamental
- Price
- RMBI $14.70
- SAVA $2.55
- Analyst Decision
- RMBI
- SAVA Buy
- Analyst Count
- RMBI 0
- SAVA 3
- Target Price
- RMBI N/A
- SAVA $111.50
- AVG Volume (30 Days)
- RMBI 19.9K
- SAVA 12.4M
- Earning Date
- RMBI 01-23-2025
- SAVA 11-07-2024
- Dividend Yield
- RMBI 3.80%
- SAVA N/A
- EPS Growth
- RMBI N/A
- SAVA N/A
- EPS
- RMBI 0.87
- SAVA N/A
- Revenue
- RMBI $42,258,740.00
- SAVA N/A
- Revenue This Year
- RMBI N/A
- SAVA N/A
- Revenue Next Year
- RMBI N/A
- SAVA N/A
- P/E Ratio
- RMBI $16.95
- SAVA N/A
- Revenue Growth
- RMBI N/A
- SAVA N/A
- 52 Week Low
- RMBI $10.11
- SAVA $2.55
- 52 Week High
- RMBI $15.15
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- RMBI 66.67
- SAVA 22.85
- Support Level
- RMBI $14.55
- SAVA $2.78
- Resistance Level
- RMBI $15.06
- SAVA $3.28
- Average True Range (ATR)
- RMBI 0.35
- SAVA 0.26
- MACD
- RMBI -0.04
- SAVA 0.25
- Stochastic Oscillator
- RMBI 47.37
- SAVA 0.00
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.